FDA approves a new two-drug combo for people on complex HIV treatment

A new single-tablet regimen has been approved by the U.S. Food and Drug Administration (FDA), making it the first daily pill for people living with HIV who are virologically suppressed while on complex, multi-tablet regimens. Bixlenvo combinesbictegravir (75 mg), an integrase strand transfer inhibitor (INSTI) with a high barrier to resistance, and lenacapavir (50 mg), a first-in-class capsid inhibitor with no cross-resistance to other antiretrovirals. Together, these drugs block HIV DNA integration and disrupt virus replication. 

Bictegravir is the key ingredient of Biktarvy, the most commonly prescribed all-in-one pill for HIV treatment. Lenacapavir is a powerful, relatively new anti-HIV drug that is used in injectable form as the six-month pair of shots for HIV prevention (PrEP), marketed as Yeztugo, and as Sunlenca, a component for an HIV regimen for people who are heavily treatment-experienced.

The FDA approved Bixlenvo based on data from phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials, which showed that the once-daily pill maintained similar virologic suppression as Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg). Bixlenvo’s two-drug combo was generally well tolerated, with no significant or new safety concerns. Detailed ARTISTRY-1 results were published in The Lancet, and ARTISTRY-2 results were published in The Lancet HIV. 

Bixlenvo’s manufacturer, Gilead Sciences, says the combination will provide a new daily treatment option for people who are aging, have comorbidities and/or want to simplify their complex regimen. An estimated 55% of the people who are diagnosed with HIV in the U.S. are age 50 or older; many have been on treatment for decades.

In a statement from Gilead, Chloe Orkin, MD, lead primary investigator of the ARTISTRY-1 trial and clinical professor of infection and inequities at Queen Mary University of London, said Bixlenvo offers a new choice for people with HIV who want to switch or streamline their treatment regimen.

“The [FDA] approval is a significant advancement in HIV treatment, especially for individuals unable to benefit from guideline-recommended [single-tablet regimens] due to challenges like pre-existing resistance or tolerability. It expands tailored, simplified dosing to people whose needs were not fully met by existing single-tablet therapies,” Dr. Orkin said. 

ARTISTRY-1 enrolled the oldest study population in a phase 3 trial for HIV-1 treatment to date, with a median participant age of 60 years, according to Gilead. At baseline, participants had been taking between two and 11 pills per day, with approximately 40% taking HIV medication more than once daily. Study participants also had extensive HIV treatment experience—with a median treatment duration of 28 years—and a high level of historical antiretroviral resistance (67% had NRTI resistance) A high proportion were on a complex regimen because of antiretroviral resistance (81%). The phase 3 results showed participants who were switched from their complex multi-tablet regimens to Bixlenvo saw improvements in certain fasting lipid parameters and reported greater treatment satisfaction. ARTISTRY-2 indicated that switching to Bixlenvo had no significant impact on weight. 

While the drugmaker believes Bixlenvo will be especially impactful for people aging with HIV, its benefits are not limited to older people. A poster session at CROI 2026 showed that Bixlenvo was just as effective at viral suppression for younger people (median age 49) as for the older group: at 48 weeks, 93% of people in the BIC/LEN group had an undetectable viral load, versus 90.6% who remained on their current treatment (Biktarvy).

Meeting an unmet need

While most people with HIV take a single-pill regimen for treatment, some rely on complex regimens, often due to drug resistance. Sometimes these regimens have strict food requirements, boosters or other factors that make daily routines difficult and ultimately may affect adherence. In addition, people who have been on treatment for decades may suffer from high pill burden and may be at risk for drug interactions because some of their medications may contain boosted protease inhibitors. According to the World Health Organization, at least 10% of adults with HIV and up to 20% of highly treatment-experienced adults have resistance to common antiretroviral drugs. 

“[Bixlenvo] represents another important step forward in the evolution of two-drug regimens, offering heavily treatment-experienced people with HIV and those on complex ART regimens an opportunity to simplify to a potent two-drug regimen with robust virologic activity,” said Aniruddha Hazra, MD, associate professor of medicine at the University of Chicago and a physician at Howard Brown Health in Chicago. “Its approval also helps set the stage for future LEN-based two-drug regimens—particularly long-acting islatravir/lenacapavir—potentially expanding simplified treatment options for people who may not be candidates for currently available two-drug regimens.”

Gilead has not announced pricing but said it will work with Medicare, Medicaid and commercial payers to help support comprehensive coverage as soon as possible. The Gilead Advancing Access program will offer information and resources to help those using the drug, and the company’s Advancing Access Co-Pay Savings Program will be available to eligible individuals. 

Dosage and administration

Bixlenvo requires a two-day initiation dose with two tablets of Sunlenca (lenacapavir), after which Bixlenvo should be taken orally once daily. Tablets may be taken with or without food. The most commonly reported side effects reported were headache, nausea and diarrhea.

Treatment with Bixlenvo with with one tablet of Bixlenvo, plus two 300 mg tablets of Sunlenca on Days 1 and 2 as loading doses. From Day 3 and thereafter, it’s Bixlenvo alone every day. If initiation doses of Bixlenvo or Sunlenca are missed, take them as soon as possible. Do not take the Day 1 and Day 2 doses of Sunlenca on the same day. Take missed regular doses as soon as possible. If more than seven days have elapsed since the last regular daily dose, restart initiation dosage regimen from Day 1, if clinically appropriate to continue treatment.

FDA approval came on August 27.

Coming soon: On the POSITIVELY AWARE YouTube channel, two upcoming installments of The PA Chat will feature interviews with three long-term survivors who took part in a clinical trial that helped lead to Bixlenvo’s approval.